evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 4 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 20%Low 2 · 40%Moderate 2 · 40%High 0 · 0%

Tiotropium vs ipratropium

Mortality (all‐cause) · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…

Tiotropium showed no clear difference in mortality (all‐cause) compared with ipratropium (moderate certainty).

1 finding from 1 review

Tiotropium vs long‐acting beta‐agonists

Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease and > 10 pack years smoking history

It is very uncertain whether tiotropium changes mortality (all‐cause) compared with long‐acting beta‐agonists (very low certainty).

1 finding from 1 review

Long‐acting beta2‐agonist plus tiotropium vs tiotropium

Mortality (all cause) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease

Long‐acting beta2‐agonist plus tiotropium showed no clear difference in mortality (all cause) compared with tiotropium alone (low certainty).

1 finding from 1 review

Tiotropium + LABA/ICS combination vs tiotropium

Mortality (all‐cause) · patients with chronic obstructive pulmonary disease

Tiotropium + LABA/ICS combination showed no clear difference in mortality (all‐cause) compared with tiotropium (moderate certainty).

1 finding from 1 review

Long‐acting beta2‐agonist plus tiotropium vs long‐acting beta2‐agonist alone

Mortality (all cause) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease

Long‐acting beta2‐agonist plus tiotropium showed no clear difference in mortality (all cause) compared with long‐acting beta2‐agonist alone (low certainty).

1 finding from 1 review